- our leadership
- Dedicating endless research and development for innovative anticancer drugs,
treatment of CNS and infectious diseases for the ultimate well-being of mankind.
- Perpetual Pharmaceutical Pearl Provider,
- ABION
“ At Abion, our objective is to develop first-ever
companion diagnostics-based drugs in Korea.”
With cutting-edge resources at our disposal, treatments will be personalized and
developed based on our patients’ individual biomarkers.
- Research & Development
- Through our national research projects, we are developing the anticancer inhibiting agent ABN401, a biobetter for treatment of multiple sclerosis, and medical countermeasures for Acute Radiation Syndrome (ARS) and infectious diseases, a lineup that we are promoting through globally certified clinical processes towards eventual commercialization across international markets.
- abion
- Anticancer Therapies
- abion
- Treatment for Multiple Sclerosis
- abion
- Medical Countermeasures (MCM)
NEWS + more
Announcement of 7th General Shareholders’ Meeting
2018년 December 23일
Date of Post: March 27, 2015 We held a workshop to kick off a fresh…
2014 Annual Reference Biolab Workshop
2018년 December 23일
Date of Post: March 27, 2015 We have held a workshop to kick off a…
NOTICE + more
Announcement of 8th Extraordinary General Shareholders’ Meeting
2018년 December 23일
Date of Post: March 27, 2015 In accordance with provisions of Article 22 in our…
Abion KONEX Certificate of Merit & Proclamation of CI Award
2018년 December 23일
Date of Post: March 27, 2015 On July 22, 2014, the Best Western Premier Hotel…